Results from a large cardiovascular study show that diabetics using Eli Lilly’s (NYSE:LLY) Jardiance had fewer heart attacks and strokes than they might have suffered otherwise. The findings, which were also reported by Jardiance co-developer Boehringer Ingelheim, could shift how doctors treat patients and lead to significant sales growth for Eli Lilly.
A new class of diabetes medicine
Eli Lilly’s once-daily Jardiance is an SGLT2-inhibiting pill that lowers blood glucose levels by blocking glucose reabsorption in the kidney.
Help employers find you! Check out all the jobs and post your resume.
